Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 341

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Open access
Ripperger, Tyler J., Uhrlaub, Jennifer L., Watanabe, Makiko, Wong, Rachel, Castaneda, Yvonne, Pizzato, Hannah A., Thompson, Mallory R., Bradshaw, Christine, Weinkauf, Craig C., Bime, Christian, Erickson, Heidi L., Knox, Kenneth, Bixby, Billie, Parthasarathy, Sairam, Chaudhary, Sachin, Natt, Bhupinder, Cristan, Elaine, El Aini, Tammer, Rischard, Franz, Campion, Janet, Chopra, Madhav, Insel, Michael, Sam, Afshin, Knepler, James L., Capaldi, Andrew P., Spier, Catherine M., Dake, Michael D., Edwards, Taylor, Kaplan, Matthew E., Scott, Serena Jain, Hypes, Cameron, Mosier, Jarrod, Harris, David T., LaFleur, Bonnie J., Sprissler, Ryan, Nikolich-Žugich, Janko, Bhattacharya, Deepta·2020·Immunity

Abstract

We conducted a serological study to define correlates of immunity against SARS-CoV-2. Compared to those with mild coronavirus disease 2019 (COVID-19) cases, individuals with severe disease exhibited elevated virus-neutralizing titers and antibodies against the nucleocapsid (N) and the receptor binding domain (RBD) of the spike protein. Age and sex played lesser roles. All cases, including asymptomatic individuals, seroconverted by 2 weeks after PCR confirmation. Spike RBD and S2 and neutralizing antibodies remained detectable through 5–7 months after onset, whereas α-N titers diminished. Testing 5,882 members of the local community revealed only 1 sample with seroreactivity to both RBD and S2 that lacked neutralizing antibodies. This fidelity could not be achieved with either RBD or S2 alone. Thus, inclusion of multiple independent assays improved the accuracy of antibody tests in low-seroprevalence communities and revealed differences in antibody kinetics depending on the antigen. We conclude that neutralizing antibodies are stably produced for at least 5–7 months after SARS-CoV-2 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.10.004

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

See all 341

Metadata

Authors
Ripperger, T. J., Uhrlaub, J. L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato, H. A., Thompson, M. R., Bradshaw, C., Weinkauf, C. C., Bime, C., Erickson, H. L., Knox, K., Bixby, B., Parthasarathy, S., Chaudhary, S., Natt, B., Cristan, E., El Aini, T., Rischard, F., Campion, J., Chopra, M., Insel, M., Sam, A., Knepler, J. L., Capaldi, A. P., Spier, C. M., Dake, M. D., Edwards, T., Kaplan, M. E., Scott, S. J., Hypes, C., Mosier, J., Harris, D. T., LaFleur, B. J., Sprissler, R., Nikolich-Žugich, J., & Bhattacharya, D.
Venue
Immunity
Publisher
Elsevier BV
Published
2020-11
Volume
53
Issue
5
Pages
925-933.e4
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3093231763
Cited by
341
References
73
FWCI
9.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. https://app.cochat.ai/papers/10.1016/j.immuni.2020.10.004
The paper
Ripperger, T. J., Uhrlaub, J. L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato, H. A., Thompson, M. R., Bradshaw, C., Weinkauf, C. C., Bime, C., Erickson, H. L., Knox, K., Bixby, B., Parthasarathy, S., Chaudhary, S., Natt, B., Cristan, E., El Aini, T., Rischard, F., . . . Bhattacharya, D. (2020). Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. https://doi.org/10.1016/j.immuni.2020.10.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.